Samrat Pharmachem Reports Strong Profit Growth Amid Declining Net Sales in February 2025

Samrat Pharmachem, a microcap player in the Pharmaceuticals & Drugs industry, has recently reported its financial results for the quarter ending December 2024. The results, declared on February 14, 2025, indicate a notable adjustment in evaluation, with the score rising to 18 from 16 over the past three months. The financial data reveals several positive trends for Samrat Pharma. The company achieved its highest operating profit (PBDIT) at Rs 4.17 crore, marking consistent growth over the last five quarters. Additionally, the operating profit margin reached 6.55%, reflecting enhanced efficiency within the organization. Profit Before Tax (PBT) also saw a peak at Rs 3.91 crore, alongside a Profit After Tax (PAT) of Rs 2.78 crore, both demonstrating a favorable trajectory in the near term. Furthermore, earnings per share (EPS) reached Rs 9.00, indicating an increase in profitability and higher returns for shareholders. Conversely, net sales reported a decline, standing at Rs 63.66 crore, which represents a decrease compared to the average net sales of the previous four quarters. This aspect highlights a contrasting trend in the company's overall performance. For more insights on Samrat Pharmachem's financial trends, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.